Nav: Home

Cancer researchers look at resistance to targeted therapy in mantle cell lymphoma

June 14, 2017

WASHINGTON (June 14, 2017) -- Today some patients suffering with mantle cell lymphoma, a type of blood cancer, can be treated with a pill called Ibrutinib, forgoing conventional chemotherapy. However, many are developing a resistance to this treatment. Research published in Nature Communications by Eduardo Sotomayor, MD, director of the George Washington University Cancer Center and Jianguo Tao, MD, PhD, senior member of the Cancer Biology and Evolution Program at Moffitt Cancer Center, details how lymphoma cells are acquiring their resistance.

"Not all patients will react to a drug in the same way," said Sotomayor. "Some will take it and no longer show symptoms of lymphoma. In others, they may not show a response to the treatment at all, and in other, after an initial response to treatment, the lymphoma may come back more aggressive than before. What we wanted to understand is: How can we make this treatment work for everyone?"

In the past, those diagnosed with mantle cell lymphoma received chemotherapy and monoclonal antibody treatments, which often led to a number of side effects. Some patients are now treated with ibrutinib, a daily pill that has been associated with significant positive response by lymphoma patients. Sotomayor and his research team wanted to understand the lymphoma cells and the mechanisms that allow them to develop resistance to the drug.

"As shown in the past by Dr. Tao's group, mantle cell lymphoma cells depend on strong interactions with the microenvironment for progression. Rather than focus on the cells themselves, our team was concerned about understanding the microenvironment where the cells thrive and find protection," Sotomayor explained. "We need to look at the tumor cells in the context of the microenvironment to understand how they build up resistance."

The team noticed that when ibrutinib shut down the bruton tyrosine kinase pathway that the lymphoma cells thrived in, the cells adapted and began to activate another pathway, noted in the study as PI3K-AKT-mTOR. This allowed the cancer cells to come back, in some cases as more aggressive. Not only did the cells adapt to the drug, they adapted to its effects on the space around them and adapted the microenvironment facilitating further progression. Exploring methods for inhibiting the pathways and resistance networks would be a next step in finding a way to make ibrutinib an even better drug for more patients.
-end-
The study titled, "Unification of de novo and Acquired Ibrutinib Resistance in Mantle Cell Lymphoma" was published in Nature Communications at https://www.ncbi.nlm.nih.gov/pubmed/28416797.

Media: To interview Dr. Sotomayor, contact Ashley Rizzardo at amrizz713@gwu.edu or 202-994-8679

About the GW Cancer Center

The George Washington University (GW) Cancer Center is a collaboration between the GW Hospital, the GW Medical Faculty Associates, the GW School of Medicine and Health Sciences, and the Milken Institute School of Public Health at GW to expand GW's efforts in the fight against cancer. The GW Cancer Center also incorporates all existing cancer-related activities at GW, serving as a platform for future cancer services and research development. Learn more about the GW Cancer Center at gwcancercenter.org.

George Washington University

Related Lymphoma Articles:

The gene behind follicular lymphoma
EPFL scientists have discovered an important gene whose loss lies behind follicular lymphoma, an incurable cancer.
Hodgkin lymphoma survivors at high risk of second cancers
Patients who are cured of Hodgkin lymphoma are at a high risk of developing a second type of cancer, particularly if they have a family history of the disease, a major new study reports.
Follicular lymphoma: A tale of 2 cancers
Many people survive well beyond 10 years following diagnosis of follicular lymphoma.
Patients with advanced lymphoma in remission after T-cell therapy
In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy.
$2.5 million boost for lymphoma research through Tanoto Foundation
The SingHealth Duke-NUS Academic Medical Centre announced today that a S$2.5 million Tanoto Foundation Professorship in Medical Oncology has been conferred to Assoc Prof Lim Soon Thye, Head and Senior Consultant of the Division of Medical Oncology at the National Cancer Centre Singapore; and Assistant Dean at Duke-NUS Medical School.
Lymphoma overrides a key protein's quadruple locks
Protein chemists at Johns Hopkins report they are closer to explaining why certain blood cancers are able to crack a molecular security system and run rampant.
Study: Bacterium that causes Q fever linked to non-Hodgkin lymphoma
The bacterium that causes Q fever, an infectious disease that humans contract from animals, is associated with an increased risk of lymphoma, according to a study published online today in Blood, the Journal of the American Society of Hematology.
Lymphoma: How the tumor escapes the immune response
Natural killer cells of the immune system can fend off malignant lymphoma cells and thus are considered a promising therapeutic approach.
Follow-up PET/CT more than 95 percent sensitive for non-Hodgkin lymphoma
Non-Hodgkin lymphoma, a potentially devastating cancer of the blood and immune system, can range from relatively easy to treat to very aggressive.
Hodgkin's lymphoma: The treatment can have late sequelae
Hodgkin's lymphoma -- cancer of the lymph nodes -- arises in more than 150 children and adolescents in Germany each year.

Related Lymphoma Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".